Velázquez-Quintana M, Sanín-Aguirre LH, Ávila-Campos JA, Díaz-López CV, López-Alonzo SJ

Language: Spanish
References: 8
Page:
PDF size: 48.78 Kb.

ABSTRACT

The aim was to determine if in Mexican, overweight or obese subjects, the Orlistat dosed at 60 mg versus Orlistat dosed at 120 mg, both oral, keeps the same therapeutic efficacy and if the gastrointestinal adverse events may be tolerated easier. Longitudinal, prospective, double blind and comparative clinical trial, with a 7 days screening period and a 90 days treatment period with random allocation of subjects. The weight loss, body mass index, body fat composition and anthropometric parameters were statistically significant inside the groups, but without difference between them (2.1 versus 1.5 kg). Most of the gastrointestinal adverse events were mild in intensity at both groups. In Mexican, overweight or obese subjects, the Orlistat dosed at 60 mg before each meal demonstrates the same effect at weight reduction than the 120 mg dose before each meal. It is recommended to use it in conjunction with dietary modification and physical activity.

REFERENCES

1. Drew BS, AF Dixon and JB Dixon 2007. Obesity management: update on orlistat.

2. Filippatos TD, CS Derdemezis, IF Gazi, ES Nakou, DP Mikhailidis and MS Elisaf 2008. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. Vol 31 No. 1: 53-65

3. Conde JL 2002. Eficacia y efectividad: una distinci ón útil para la práctica y la investigación clínicas. Nefrología. Vol. 22 No. 3: 219-222.

4. Hauptman J, C Lucas, MN Boldrin, H Collins and Segal K 2000. Orlistat in the long-term treatment of obesity in the primary care setting. Arch. Fam. Med . Vol. 9 No. 2: 160-167.

5. Anderson JW 2007. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother. Vol. 8 No. 11: 1733-1742

6. Goldstein DJ 1992. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. Vol.16 No. 6: 397-415.

7. Rössner S, L Sjöström, R Noack, AE Meinders and G Noseda 2000. Weight loss, weight maintenance, and improved cardiovascular risk factor after 2 years treatment with Orlistat for obesity. Obesity Research. Vol. 8 No. 1: 49-61.

8. Hauptman J, et al, Op cit